GLS Stock Overview
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Glenmark Life Sciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹776.65 |
52 Week High | ₹906.00 |
52 Week Low | ₹380.00 |
Beta | 0.16 |
1 Month Change | -12.57% |
3 Month Change | 18.20% |
1 Year Change | 103.02% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 3.76% |
Recent News & Updates
Shareholder Returns
GLS | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 3.5% | 2.4% | 1.8% |
1Y | 103.0% | 65.8% | 48.6% |
Return vs Industry: GLS exceeded the Indian Pharmaceuticals industry which returned 63.9% over the past year.
Return vs Market: GLS exceeded the Indian Market which returned 47.3% over the past year.
Price Volatility
GLS volatility | |
---|---|
GLS Average Weekly Movement | 5.5% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: GLS has not had significant price volatility in the past 3 months.
Volatility Over Time: GLS's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,824 | Yasir Rawjee | https://www.glenmarklifesciences.com |
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies.
Glenmark Life Sciences Limited Fundamentals Summary
GLS fundamental statistics | |
---|---|
Market cap | ₹95.16b |
Earnings (TTM) | ₹5.19b |
Revenue (TTM) | ₹23.68b |
18.3x
P/E Ratio4.0x
P/S RatioIs GLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLS income statement (TTM) | |
---|---|
Revenue | ₹23.68b |
Cost of Revenue | ₹10.76b |
Gross Profit | ₹12.91b |
Other Expenses | ₹7.72b |
Earnings | ₹5.19b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 42.38 |
Gross Margin | 54.54% |
Net Profit Margin | 21.93% |
Debt/Equity Ratio | 0.8% |
How did GLS perform over the long term?
See historical performance and comparison